Small transpacific team led by Lilly, Everest vet turns to computational tools for next wave of peptide drug discovery
When Kerry Blanchard left Everest Medicines in August 2022 to make room for a CEO with a commercial background, he didn’t have a full idea of what he was doing next. But having spent the past decade in drug development, the scientist and physician by training knew the direction he wanted to go.
“I’ve been very interested in moving back into discovery,” Blanchard said.
A few months later, he jumped right in with a new startup, Perpetual Medicines, that’s focused on applying computational methods to peptide therapies, which he believes will be the fastest-growing area in pharma over the next 20 years. Now, Blanchard, the co-founder and CEO, is taking the wraps off an $8 million seed round led by Chengwei Capital.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.